europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

What if we could prevent childhood blindness

01/01/2020
FACTSHEET
What if we could prevent childhood blindness

Genome surgery for eye diseases is fast approaching

Solution: Genome editing dysfunctional cells in the eye could be a cure for one type of childhood blindness.

Did you know?
The eye lends itself well to genome editing, which is why early research is happening here. If successful, the research could move to other tissues as well. Progress like this helps move toward the third UN Sustainable Development Goal of Good Health and Well-Being.

Leber congenital amaurosis (LCA) is a rare hereditary eye disease that is the most common form of childhood blindness. It appears at birth or in the first few months of life and affects 1 in 40.000 newborns. Symptoms include significant vision loss within the first year of life and rapid involuntary eye movement, ultimately ending in blindness. LCA type 10 is the most common form of the disorder and accounts for 20-30% of all LCA subtypes. No treatment currently exists.

A genetic mutation is the cause of the illness and will also be the target of a potential cure. The mutation causes the progressive loss of the eye’s light-detecting cells, called photoreceptors. Editas Medicine has developed a therapy that makes use of CRISPR genome editing to correct the mutation directly in the eye. CRISPR is a precision genetic engineering tool which allows scientists to change individual letters of the genetic code with high efficiency and relative ease. The CRISPR molecules can be delivered to the eye by subretinal injection, where they enter the cells of the retina and edit the mutated gene. This intervention has the potential to restore the function of remaining photoreceptor cells and arrest further loss of vision for patients.

Editas Medicine acquired the permission of the US Food and Drug Administration at the end of 2018 to test their therapy in patients. This will be the first clinical trial using CRISPR genome editing directly in patients. Its successful use will be a milestone for medical science and could unlock the cure to many genetic diseases.

What if we could prevent childhood blindness


Download
2020_01_H_F_EuropaBIO_WHATIF_blindness_V01Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more
01/03/2023

Vlad Olteanu new Healthcare Public Affairs Director at EuropaBio


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies